Evaluation of Dosing Interval of Higher Doses of Ranibizumab

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brandon G. Busbee, MD
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Treatment naive macular degeneration patients with choroidal neovascularization

• >50 years old

• Visual acuity 20/40 to 20/320

Exclusion Criteria:

• Pregnancy

• Previous history of thromboembolic event including myocardial infarction or stroke